€23.15
0.22% yesterday
Xetra, Sep 04, 05:35 pm CET
ISIN
DE000A1EWVY8
Symbol
FYB
Index

Formycon Stock price

€23.15
-3.65 13.62% 1M
-2.20 8.68% 6M
-29.95 56.40% YTD
-28.85 55.48% 1Y
-50.85 68.72% 3Y
-1.85 7.40% 5Y
-0.92 3.80% 10Y
+14.25 160.11% 20Y
Xetra, Closing price Thu, Sep 04 2025
-0.05 0.22%
ISIN
DE000A1EWVY8
Symbol
FYB
Index
Industry

Key metrics

Basic
Market capitalization
€424.0m
Enterprise Value
€407.0m
Net debt
positive
Cash
€27.3m
Shares outstanding
17.7m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
8.2 | 7.8
EV/Sales
7.9 | 7.5
EV/FCF
negative
P/B
1.0
Financial Health
Equity Ratio
59.9%
Return on Equity
-27.2%
ROCE
-5.3%
ROIC
-4.9%
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
€51.8m | €54.4m
EBITDA
€-35.7m | €-19.8m
EBIT
€-37.0m | €-37.0m
Net Income
€-169.8m | €-31.6m
Free Cash Flow
€-22.3m
Growth (TTM | estimate)
Revenue
-14.8% | -22.0%
EBITDA
-48.3% | 10.0%
EBIT
-49.5% | -57.1%
Net Income
-365.7% | 74.9%
Free Cash Flow
62.2%
Margin (TTM | estimate)
Gross
-1.0%
EBITDA
-68.9% | -36.4%
EBIT
-71.4%
Net
-327.9% | -58.1%
Free Cash Flow
-43.1%
More
EPS
€-9.6
FCF per Share
€-1.3
Short interest
-
Employees
250
Rev per Employee
€280.0k
Show more

Is Formycon a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,003 stocks worldwide.

Formycon Stock Analysis

Unlock Scores for Free

Analyst Opinions

13 Analysts have issued a Formycon forecast:

11x Buy
85%
2x Hold
15%

Analyst Opinions

13 Analysts have issued a Formycon forecast:

Buy
85%
Hold
15%

Financial data from Formycon

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
52 52
15% 15%
100%
- Direct Costs 52 52
2% 2%
101%
-0.51 -0.51
107% 107%
-1%
- Selling and Administrative Expenses 20 20
14% 14%
38%
- Research and Development Expense 15 15
10% 10%
29%
-36 -36
48% 48%
-69%
- Depreciation and Amortization 1.26 1.26
94% 94%
2%
EBIT (Operating Income) EBIT -37 -37
50% 50%
-71%
Net Profit -170 -170
366% 366%
-328%

In millions EUR.

Don't miss a Thing! We will send you all news about Formycon directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Formycon Stock News

AD HOC NEWS
23 days ago
Die Aktien von Formycon DE000A1EWVY8 haben am Mittwoch mit klaren Verlusten auf die Halbjahreszahlen des Arzneimittel-Herstellers reagiert.
More Formycon News

Company Profile

Formycon AG engages in the manufacture of biosimilar drugs and formulations. Its product candidates include FYB201, FYB202, FYB203, and FYB205 which focusoin the opthalmology and immunology disease areas. The company was founded by Friedrich Wilhelm Steinweg and Nicolas Combé in 2007 and is headquartered in Munich, Germany.

Head office Germany
CEO Stefan Glombitza
Employees 250
Founded 2007
Website www.formycon.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today